本报告导读：公司血液瘤业务在奥布替尼、ICP-248 等产品的推进，领导地位持续巩固；自免领带多管线多适应症进入III 期。投资要点：给予“增持”评级。我们预计2025-27 年公司营收分别为14.43/18.59/26.91 亿元，分别同比增长43/29/45%。参考可比公司，我们给予诺诚健华2025 年30 倍PS，目标价为24.53 元/26.70 港元（汇率为1 港元=0.92 人民币），...
Source Link本报告导读：公司血液瘤业务在奥布替尼、ICP-248 等产品的推进，领导地位持续巩固；自免领带多管线多适应症进入III 期。投资要点：给予“增持”评级。我们预计2025-27 年公司营收分别为14.43/18.59/26.91 亿元，分别同比增长43/29/45%。参考可比公司，我们给予诺诚健华2025 年30 倍PS，目标价为24.53 元/26.70 港元（汇率为1 港元=0.92 人民币），...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.